Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00462358 · ClinicalTrials.gov registry record · Phase 1

A Study of ARRY-520 in Patients With Advanced Cancer

A Phase 1 study of Advanced Solid Tumors, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 1
Development phase
41
Enrollment target
2
Study locations

NCT00462358 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Array Biopharma, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 41 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00462358, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
41 participants
Enrollment target
2
Study locations

Study Summary

This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-520. This study has two parts. In the first part, patients with advanced solid tumors will receive increasing doses of study drug, with or without granulocyte-colony stimulating factor (G-CSF) support, in order to achieve the highest dose possible that will not cause unacceptable side effects. Approximately 15 patients (per schedule) from the US will be enrolled in Part 1 (Completed). In the second part of the study, patients will receive the best dose of study drug determined from the first part of the study and will be followed to evaluate what side effects the study drug causes and what effectiveness it has, if any, in treating the cancer. Approximately 15 patients from the US will be enrolled in Part 2 (Completed).

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG ARRY-520, KSP(Eg5) inhibitor; intravenous
  • DRUG Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Study Locations (2)

Maryland

  • Marlene and Stewart Greenebaum Cancer Center - Baltimore

Michigan

  • Wayne State University, Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2007-04
Est. Completion 2010-11
Phase Phase 1

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer

21 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00462358

The ClinicalTrials.gov registry entry for NCT00462358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (79% lower). The listed sponsor is Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which ARRY-520, KSP(Eg5) inhibitor; intravenous is the first listed.

NCT00462358 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Michigan.

Frequently Asked Questions

What is clinical trial NCT00462358 about?

NCT00462358 is a clinical study titled "A Study of ARRY-520 in Patients With Advanced Cancer". This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-520. This study has two parts. In the first part, patients with advanced solid tumors will receive increasing doses of study drug, with or without granulocyte-colony stimulating fac...

What is the current status of trial NCT00462358?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2007-04. Estimated completion is 2010-11.

What conditions does trial NCT00462358 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT00462358?

The interventions under investigation include: ARRY-520, KSP(Eg5) inhibitor; intravenous (DRUG), Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous (DRUG).

Who is sponsoring clinical trial NCT00462358?

This trial is sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00462358 being conducted?

This trial has 2 study locations across Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.